Compare AKA & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKA | SERA |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.4M | 75.2M |
| IPO Year | 2021 | 2021 |
| Metric | AKA | SERA |
|---|---|---|
| Price | $9.62 | $2.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $24.33 | N/A |
| AVG Volume (30 Days) | 4.4K | ★ 55.2K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $600,208,000.00 | $81,000.00 |
| Revenue This Year | $6.14 | $554.81 |
| Revenue Next Year | $4.89 | $517.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 4.44 | ★ 5.19 |
| 52 Week Low | $8.60 | $1.37 |
| 52 Week High | $16.38 | $4.09 |
| Indicator | AKA | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 60.53 |
| Support Level | $8.94 | $1.73 |
| Resistance Level | $11.83 | $2.41 |
| Average True Range (ATR) | 0.60 | 0.25 |
| MACD | -0.20 | 0.05 |
| Stochastic Oscillator | 11.18 | 71.63 |
a.k.a. Brands Holding Corp is a portfolio of fashion brands, including Princess Polly, Culture Kings, Petal & Pup, and mnml. Through these brands, the company reaches next-generation consumers who seek fashion inspiration on social media and mainly shop online. The portfolio consists of two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company generates the majority of its revenue from the United States.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.